DAT gene polymorphisms (rs28363170, rs393795) and levodopa-induced dyskinesias in Parkinson's disease
Authors:
- 1 January 2019
- journal article
- research article
- Published by Elsevier in Neuroscience Letters
- Vol. 690, 83-88
Abstract
No abstract availableKeywords
Funding Information
- Italian Ministry of University and Research
This publication has 44 references indexed in Scilit:
- Polymorphisms in the dopamine transporter gene are associated with visual hallucinations and levodopa equivalent dose in Brazilians with Parkinson's diseaseInternational Journal of Neuropsychopharmacology, 2013
- Systematic review of levodopa dose equivalency reporting in Parkinson's diseaseMovement Disorders, 2010
- Genetic polymorphisms in the DRD2, DRD3, and SLC6A3 gene in elderly patients with deliriumAmerican Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2009
- Dopamine Transporter Genetic Variants and Pesticides in Parkinson’s DiseaseEnvironmental Health Perspectives, 2009
- BDNF val66met influences time to onset of levodopa induced dyskinesia in Parkinson's diseaseJournal of Neurology, Neurosurgery & Psychiatry, 2009
- Striatal Dopamine Transporter Availability Associated with Polymorphisms in the Dopamine Transporter Gene SLC6A3Journal of Nuclear Medicine, 2008
- Genotype and smoking history affect risk of levodopa‐induced dyskinesias in Parkinson's diseaseMovement Disorders, 2006
- Sydney multicenter study of Parkinson's disease: Non‐L‐dopa–responsive problems dominate at 15 yearsMovement Disorders, 2004
- Body weight, levodopa pharmacokinetics and dyskinesia in Parkinson's diseaseNeurological Sciences, 2002
- Polymorphisms in the 3′-untranslated region of human and monkey dopamine transporter genes affect reporter gene expressionMolecular Psychiatry, 2002